Treatment of Streptocococcus anginosus Infective Endocarditis
Treat Streptococcus anginosus endocarditis with penicillin G (12-18 million units/day IV) or ceftriaxone (2g/day IV) for 4 weeks for native valve endocarditis, adding gentamicin (3 mg/kg/day) for the first 2 weeks, with 6-week therapy for prosthetic valve cases. 1
Treatment Algorithm Based on Valve Type and Penicillin Susceptibility
Native Valve Endocarditis
S. anginosus is classified within the viridans group streptococci (VGS) and typically demonstrates penicillin susceptibility (MIC ≤0.125 mg/L) 2. The treatment approach follows VGS guidelines:
For penicillin-susceptible strains:
- Penicillin G 12-18 million units/day IV in 4-6 divided doses for 4 weeks, OR
- Ceftriaxone 2g/day IV in 1 dose for 4 weeks (particularly convenient for outpatient therapy)
- Add gentamicin 3 mg/kg/day IV for the first 2 weeks 1
The 2-week gentamicin addition is critical because S. anginosus has a propensity for abscess formation—unlike other viridans streptococci—and may require more aggressive initial therapy 1. This organism commonly produces cardiac abscesses and may necessitate adjunctive surgery 1.
Prosthetic Valve Endocarditis
Extend all therapy to 6 weeks for prosthetic valve involvement 3, 1. The same antibiotic regimens apply, but the longer duration is essential given the higher mortality risk with prosthetic valve S. anginosus endocarditis 1.
Recent data suggests 4-week therapy may be adequate for prosthetic valve streptococcal endocarditis without increased adverse outcomes, though 6 weeks remains the guideline recommendation 4.
Alternative Regimens
For penicillin-allergic patients:
- Vancomycin 30 mg/kg/day IV in 2 divided doses for 4 weeks (native valve) or 6 weeks (prosthetic valve) 3
- Do NOT add gentamicin to vancomycin regimens 3
For penicillin-resistant strains (MIC ≥0.5 μg/mL):
- Treat as enterococcal endocarditis with ampicillin or penicillin PLUS gentamicin with infectious disease consultation 3
- Consider ceftriaxone plus gentamicin if ceftriaxone-susceptible 3
Critical Clinical Considerations
Abscess Formation Risk
S. anginosus differs from other viridans streptococci by its strong association with abscess formation 1, 2. Actively search for:
- Cardiac abscesses/pseudoaneurysms (occur in ~18% of streptococcal IE cases) 5
- Embolic complications (occur in ~25% of cases) 5
- Extracardiac abscesses (brain, liver, spleen) 6, 7
Surgical Intervention
Consider early cardiac surgery for:
- Cardiac abscess formation
- Severe valvular dysfunction
- Persistent bacteremia despite appropriate antibiotics
- Large vegetations with embolic events
Surgery was performed in 55% of streptococcal IE cases in one large series, and is particularly important for Group B streptococci (which includes S. anginosus group) given high mortality with prosthetic valve involvement 1, 5.
Monitoring and Follow-up
- Obtain repeat blood cultures after 48-72 hours to document clearance
- Perform serial echocardiography to monitor vegetation size and detect complications
- S. anginosus bacteremia should prompt aggressive investigation for IE, especially if recovered in multiple blood cultures 2
Special Populations
Elderly patients (>65 years): Prefer penicillin G over aminoglycoside-containing regimens due to nephrotoxicity and ototoxicity risk 1
Renal impairment: Avoid or adjust gentamicin dosing; single daily dosing of gentamicin (3 mg/kg) is preferred when used 3, 1
Common Pitfalls
Misidentification: Commercial systems (Vitek, API) often fail to accurately identify S. anginosus at >95% confidence; 16S rRNA sequencing may be needed 2
Underestimating abscess risk: Unlike typical viridans streptococci, S. anginosus requires heightened vigilance for abscess formation both cardiac and extracardiac 1, 7
Inadequate source control: Medical therapy alone may be insufficient—67% of disseminated S. anginosus infections required surgical drainage in addition to antibiotics 7
Premature discontinuation: Even with clinical improvement, complete the full 4-6 week course to prevent relapse